← Calendar
Readoutin 14d
Madrigal Pharmaceuticals, Inc. — Resmetirom
Phase 3 primary completion: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES).
- Date
- Dec 2026
- Type
- Readout
- Indication
- NASH
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from Madrigal Pharmaceuticals, Inc.
Mar2027
Readoutin 104d
Madrigal Pharmaceuticals, Inc. — ResmetiromPhase 3 primary completion: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE).